Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Harrison

Showing results (511-520 of 584) with videos related to

Pageof 59
Sort By:
Hemasphere|May 10, 2021
Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 TrialClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Cell Reports|January 19, 2023
VGLL2-NCOA2 leverages developmental programs for pediatric sarcomagenesisSarah Watson, Collette A LaVigne, Lin Xu, et al.
British Journal of Haematology|January 28, 2009
Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clonesPhilip A Beer, Amy V Jones, Anthony J Bench, et al.
Blood Advances|February 18, 2021
Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signatureSamah Alimam, William Villiers, Richard Dillon, et al.
Nature Communications|May 22, 2026
Reentrant Landau levels in a Dirac topological insulatorC Kaufmann Ribeiro, J C Mutch, Q Jiang, et al.
British Journal of Haematology|May 16, 2013
Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapyClaire N Harrison, Ruben A Mesa, Jean-Jacques Kiladjian, et al.
Leukemia|May 23, 2021
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasmsPatrick Harrington, Hugues de Lavallade, Katie J Doores, et al.
Hemasphere|July 11, 2020
Longitudinal Cytokine Profiling Identifies GRO-α and EGF as Potential Biomarkers of Disease Progression in Essential ThrombocythemiaNina F Øbro, Jacob Grinfeld, Miriam Belmonte, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 8, 2024
Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With MomelotinibClaire N Harrison, Ruben Mesa, Moshe Talpaz, et al.
Hemasphere|November 1, 2023
Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 TrialsJean-Jacques Kiladjian, Alessandro M Vannucchi, Aaron T Gerds, et al.
Pageof 59

Showing results (511-520 of 584) with videos related to

Sort By:
Pageof 59
Hemasphere|May 10, 2021
Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 TrialClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Cell Reports|January 19, 2023
VGLL2-NCOA2 leverages developmental programs for pediatric sarcomagenesisSarah Watson, Collette A LaVigne, Lin Xu, et al.
British Journal of Haematology|January 28, 2009
Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clonesPhilip A Beer, Amy V Jones, Anthony J Bench, et al.
Blood Advances|February 18, 2021
Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signatureSamah Alimam, William Villiers, Richard Dillon, et al.
Nature Communications|May 22, 2026
Reentrant Landau levels in a Dirac topological insulatorC Kaufmann Ribeiro, J C Mutch, Q Jiang, et al.
British Journal of Haematology|May 16, 2013
Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapyClaire N Harrison, Ruben A Mesa, Jean-Jacques Kiladjian, et al.
Leukemia|May 23, 2021
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasmsPatrick Harrington, Hugues de Lavallade, Katie J Doores, et al.
Hemasphere|July 11, 2020
Longitudinal Cytokine Profiling Identifies GRO-α and EGF as Potential Biomarkers of Disease Progression in Essential ThrombocythemiaNina F Øbro, Jacob Grinfeld, Miriam Belmonte, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 8, 2024
Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With MomelotinibClaire N Harrison, Ruben Mesa, Moshe Talpaz, et al.
Hemasphere|November 1, 2023
Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 TrialsJean-Jacques Kiladjian, Alessandro M Vannucchi, Aaron T Gerds, et al.
Pageof 59